君實生物(01877.HK):擬以現金向蘇州君實增資4億元
格隆匯 8 月 29日丨君實生物(01877.HK)公佈,根據戰略規劃和經營發展需要,公司擬以現金向全資子公司蘇州君實增資擴股, 增資金額為人民幣4億元;蘇州君實與公司全資子公司蘇州眾合生物醫藥科技有限公司(“蘇州眾合”)擬對蘇州君奧增資擴股,方案如下:
蘇州君實以現金對蘇州君奧增資人民幣2.375億元,蘇州眾合以現金對蘇州君奧增資人民幣1250萬元;蘇州君實擬 以現金對蘇州君實工程增資擴股,增資金額為14895萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.